1622905-82-1Relevant articles and documents
Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine- 7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents
Giordanetto, Fabrizio,Barlaam, Bernard,Berglund, Susanne,Edman, Karl,Karlsson, Olle,Lindberg, Jan,Nylander, Sven,Inghardt, Tord
, p. 3936 - 3943 (2014/09/03)
Optimization of AZD6482 (2), the first antiplatelet PI3Kβ inhibitor evaluated in man, focused on improving the pharmacokinetic profile to a level compatible with once daily oral dosing as well as achieving adequate selectivity towards PI3Kα to minimize the risk for insulin resistance. Structure-based design and optimization of DMPK properties resulted in (R)-16, a novel, orally bioavailable PI3Kβ inhibitor with potent in vivo anti-thrombotic effect with excellent separation to bleeding risk and insulin resistance.